Seoul Yes Bio Co., Ltd., which is engaged in the research, development, and commercialization of advanced regenerative medicine, is accelerating its R&D efforts. Since February, the revised Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals (the Advanced Regenerative Medicine Act) has been fully implemented.

The company announced that it completed the domestic patent registration on February 20 for the “Cartilage Cultivation System Using Biomaterials for Tissue Repair,” which was filed last July. Seoul Yes Bio Co., Ltd. and Seoul Yes Hospital jointly filed and registered this patent.

The newly registered patent for the “Cartilage Cultivation System Using Biomaterials for Tissue Repair” is a technology that enables effective cartilage regeneration by harvesting a patient’s cartilage tissue with minimal invasiveness, culturing and proliferating it, and then transplanting it into the patient’s damaged cartilage site. It is expected to significantly aid in the regeneration of damaged cartilage tissue in patients with knee osteoarthritis when applied clinically.

Since its founding, the company has been at the forefront of developing cell therapies for advanced regenerative medicine clinical research and treatment, and has previously filed three patents related to bone marrow stem cell culture for the treatment of cartilage regeneration and arthritis.

Kim Song-shin, CEO of Seoul Yes Bio Co., Ltd., stated, “We expect the technology covered by this newly registered patent to demonstrate efficacy in treating arthritis and related conditions when used in combination with our existing stem cell therapies.” He added, “We plan to conduct advanced regenerative medicine clinical research to verify the therapeutic efficacy of this technology and further develop it into a therapeutic agent.”

Meanwhile, Seoul Yes Bio Co., Ltd. is a cell therapy R&D company established with investment from Seoul Yes Hospital to conduct clinical research and treatment in advanced regenerative medicine. In line with the amendment to the Advanced Regenerative Medicine Act, the company plans to conduct clinical research on advanced regenerative medicine jointly with Seoul Yes Hospital by 2025, based on the cell therapies it has developed to date.